Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	heparan sulfate 6-O-sulfotransferase activity	HS6ST2 HS6ST1 HS6ST3	2.09e-08	3	56	3	GO:0017095
GeneOntologyMolecularFunction	sulfotransferase activity	CHST15 HS6ST2 HS6ST1 WSCD2 HS6ST3	4.52e-07	55	56	5	GO:0008146
GeneOntologyMolecularFunction	transferase activity, transferring sulphur-containing groups	CHST15 HS6ST2 HS6ST1 WSCD2 HS6ST3	2.01e-06	74	56	5	GO:0016782
GeneOntologyMolecularFunction	heparan sulfate sulfotransferase activity	HS6ST2 HS6ST1 HS6ST3	9.28e-06	15	56	3	GO:0034483
GeneOntologyMolecularFunction	non-membrane spanning protein tyrosine kinase activity	JAK1 JAK2 LCK	2.91e-04	46	56	3	GO:0004715
GeneOntologyMolecularFunction	growth hormone receptor binding	JAK1 JAK2	3.43e-04	10	56	2	GO:0005131
GeneOntologyMolecularFunction	protein antigen binding	LPA LCK	9.04e-04	16	56	2	GO:1990405
GeneOntologyMolecularFunction	polypeptide N-acetylgalactosaminyltransferase activity	GALNT15 GALNT9	1.42e-03	20	56	2	GO:0004653
GeneOntologyMolecularFunction	phospholipase activator activity	LCK NSMAF	1.88e-03	23	56	2	GO:0016004
GeneOntologyMolecularFunction	lipase activator activity	LCK NSMAF	2.59e-03	27	56	2	GO:0060229
GeneOntologyBiologicalProcess	growth hormone receptor signaling pathway via JAK-STAT	JAK1 JAK2 STAT5B	2.24e-06	10	56	3	GO:0060397
GeneOntologyBiologicalProcess	heparan sulfate proteoglycan biosynthetic process, enzymatic modification	HS6ST2 HS6ST1 HS6ST3	4.10e-06	12	56	3	GO:0015015
GeneOntologyBiologicalProcess	heparan sulfate proteoglycan metabolic process	HS6ST2 HS6ST1 HS6ST3	1.25e-05	17	56	3	GO:0030201
GeneOntologyBiologicalProcess	proteoglycan biosynthetic process	CHST15 HS6ST2 HS6ST1 HS6ST3	3.91e-05	70	56	4	GO:0030166
GeneOntologyBiologicalProcess	growth hormone receptor signaling pathway	JAK1 JAK2 STAT5B	4.72e-05	26	56	3	GO:0060396
GeneOntologyBiologicalProcess	cellular response to growth hormone stimulus	JAK1 JAK2 STAT5B	5.29e-05	27	56	3	GO:0071378
GeneOntologyBiologicalProcess	heparan sulfate proteoglycan biosynthetic process	HS6ST2 HS6ST1 HS6ST3	1.17e-04	35	56	3	GO:0015012
GeneOntologyBiologicalProcess	proteoglycan metabolic process	CHST15 HS6ST2 HS6ST1 HS6ST3	1.40e-04	97	56	4	GO:0006029
GeneOntologyBiologicalProcess	response to interleukin-3	JAK1 JAK2	1.51e-04	7	56	2	GO:0036015
GeneOntologyBiologicalProcess	cellular response to interleukin-3	JAK1 JAK2	1.51e-04	7	56	2	GO:0036016
GeneOntologyBiologicalProcess	response to growth hormone	JAK1 JAK2 STAT5B	1.88e-04	41	56	3	GO:0060416
GeneOntologyBiologicalProcess	response to interleukin-2	JAK1 STAT5B	3.92e-04	11	56	2	GO:0070669
GeneOntologyBiologicalProcess	glycoprotein biosynthetic process	GALNT15 CHST15 HS6ST2 HS6ST1 GALNT9 HS6ST3	4.04e-04	357	56	6	GO:0009101
GeneOntologyBiologicalProcess	positive regulation of gamma-delta T cell differentiation	LCK STAT5B	4.70e-04	12	56	2	GO:0045588
GeneOntologyBiologicalProcess	positive regulation of natural killer cell proliferation	JAK2 STAT5B	4.70e-04	12	56	2	GO:0032819
GeneOntologyBiologicalProcess	response to interleukin-15	JAK1 STAT5B	4.70e-04	12	56	2	GO:0070672
HumanPheno	Ecchymosis	MPL JAK2 F13B STAT5B	7.84e-05	58	21	4	HP:0031364
HumanPheno	Gingival bleeding	MPL JAK2 F13B STAT5B	8.96e-05	60	21	4	HP:0000225
HumanPheno	Oral bleeding	MPL JAK2 F13B STAT5B	8.96e-05	60	21	4	HP:0000167
Domain	Heparan_SO4-6-sulfoTrfase	HS6ST2 HS6ST1 HS6ST3	2.70e-08	3	57	3	IPR010635
Domain	Sulfotransfer_2	HS6ST2 HS6ST1 HS6ST3	5.81e-06	12	57	3	PF03567
Domain	Sulfotransferase	HS6ST2 HS6ST1 HS6ST3	5.81e-06	12	57	3	IPR005331
Domain	Tyr_kinase_non-rcpt_Jak/Tyk2	JAK1 JAK2	5.47e-05	4	57	2	IPR016251
Domain	TLV_coat	ERVV-2 ERVV-1	1.90e-04	7	57	2	PF00429
Domain	TLV/ENV_coat_polyprotein	ERVV-2 ERVV-1	2.53e-04	8	57	2	IPR018154
Domain	SH2	JAK1 JAK2 LCK STAT5B	3.54e-04	110	57	4	SM00252
Domain	SH2	JAK1 JAK2 LCK STAT5B	3.66e-04	111	57	4	PS50001
Domain	SH2	JAK1 JAK2 LCK STAT5B	3.79e-04	112	57	4	IPR000980
Domain	-	JAK1 JAK2 LCK STAT5B	3.79e-04	112	57	4	3.30.505.10
Domain	TyrKc	JAK1 JAK2 LCK	2.46e-03	88	57	3	SM00219
Domain	Tyr_kinase_cat_dom	JAK1 JAK2 LCK	2.46e-03	88	57	3	IPR020635
Domain	Cadherin_cytoplasmic-dom	DSC3 CDH10	2.62e-03	25	57	2	IPR000233
Domain	Ricin_B_lectin	GALNT15 GALNT9	2.62e-03	25	57	2	PF00652
Domain	Cadherin_C	DSC3 CDH10	2.62e-03	25	57	2	PF01049
Domain	PROTEIN_KINASE_TYR	JAK1 JAK2 LCK	3.24e-03	97	57	3	PS00109
Domain	Tyr_kinase_AS	JAK1 JAK2 LCK	3.24e-03	97	57	3	IPR008266
Domain	RICIN	GALNT15 GALNT9	3.29e-03	28	57	2	SM00458
Domain	RICIN_B_LECTIN	GALNT15 GALNT9	3.29e-03	28	57	2	PS50231
Domain	Catenin_binding_dom	DSC3 CDH10	3.52e-03	29	57	2	IPR027397
Domain	-	DSC3 CDH10	3.52e-03	29	57	2	4.10.900.10
Domain	SH2	JAK2 LCK STAT5B	3.63e-03	101	57	3	PF00017
Domain	Ricin_B_lectin	GALNT15 GALNT9	3.77e-03	30	57	2	IPR000772
Domain	Glycos_transf_2	GALNT15 GALNT9	3.77e-03	30	57	2	PF00535
Domain	Glyco_trans_2-like	GALNT15 GALNT9	3.77e-03	30	57	2	IPR001173
Domain	P-loop_NTPase	MDN1 CHST15 HS6ST2 HS6ST1 HELZ2 WSCD2 POLQ HS6ST3	4.02e-03	848	57	8	IPR027417
Domain	CADHERIN_1	CLSTN3 DSC3 CDH10	4.98e-03	113	57	3	PS00232
Domain	Cadherin	CLSTN3 DSC3 CDH10	4.98e-03	113	57	3	PF00028
Domain	CADHERIN_2	CLSTN3 DSC3 CDH10	5.10e-03	114	57	3	PS50268
Domain	-	CLSTN3 DSC3 CDH10	5.10e-03	114	57	3	2.60.40.60
Domain	CA	CLSTN3 DSC3 CDH10	5.23e-03	115	57	3	SM00112
Domain	Cadherin-like	CLSTN3 DSC3 CDH10	5.35e-03	116	57	3	IPR015919
Domain	Cadherin	CLSTN3 DSC3 CDH10	5.61e-03	118	57	3	IPR002126
Domain	Pkinase_Tyr	JAK1 JAK2 LCK	7.18e-03	129	57	3	PF07714
Domain	Ser-Thr/Tyr_kinase_cat_dom	JAK1 JAK2 LCK	8.63e-03	138	57	3	IPR001245
Pathway	BIOCARTA_IL22BP_PATHWAY	JAK1 JAK2 STAT5B	2.04e-06	9	42	3	MM1419
Pathway	BIOCARTA_IL22BP_PATHWAY	JAK1 JAK2 STAT5B	2.04e-06	9	42	3	M8066
Pathway	REACTOME_INTERLEUKIN_2_SIGNALING	JAK1 LCK STAT5B	5.31e-06	12	42	3	M27893
Pathway	WP_GLYCOSAMINOGLYCAN_SYNTHESIS_IN_FIBROBLASTS	CHST15 HS6ST2 HS6ST1 HS6ST3	6.36e-06	41	42	4	M48095
Pathway	REACTOME_INTERLEUKIN_2_FAMILY_SIGNALING	JAK1 JAK2 LCK STAT5B	8.47e-06	44	42	4	M1012
Pathway	WP_THYMIC_STROMAL_LYMPHOPOIETIN_TSLP_SIGNALING	JAK1 JAK2 LCK STAT5B	1.11e-05	47	42	4	M39380
Pathway	BIOCARTA_IL7_PATHWAY	JAK1 LCK STAT5B	1.34e-05	16	42	3	M1296
Pathway	BIOCARTA_IL7_PATHWAY	JAK1 LCK STAT5B	1.34e-05	16	42	3	MM1420
Pathway	KEGG_MEDICUS_REFERENCE_HORMONE_LIKE_CYTOKINE_TO_JAK_STAT_SIGNALING_PATHWAY	MPL JAK2 STAT5B	1.62e-05	17	42	3	M47905
Pathway	REACTOME_SIGNALING_BY_KIT_IN_DISEASE	JAK2 LCK STAT5B	2.71e-05	20	42	3	M39002
Pathway	BIOCARTA_IL2_PATHWAY	JAK1 LCK STAT5B	3.64e-05	22	42	3	M7747
Pathway	BIOCARTA_IL2_PATHWAY	JAK1 LCK STAT5B	4.18e-05	23	42	3	MM1411
Pathway	BIOCARTA_TPO_PATHWAY	MPL JAK2 STAT5B	4.77e-05	24	42	3	M11520
Pathway	REACTOME_INACTIVATION_OF_CSF3_G_CSF_SIGNALING	JAK1 JAK2 STAT5B	5.40e-05	25	42	3	M41829
Pathway	BIOCARTA_TPO_PATHWAY	MPL JAK2 STAT5B	5.40e-05	25	42	3	MM1519
Pathway	REACTOME_INTERLEUKIN_20_FAMILY_SIGNALING	JAK1 JAK2 STAT5B	6.10e-05	26	42	3	M27750
Pathway	KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN_SULFATE	HS6ST2 HS6ST1 HS6ST3	6.10e-05	26	42	3	M7330
Pathway	REACTOME_HS_GAG_BIOSYNTHESIS	HS6ST2 HS6ST1 HS6ST3	8.51e-05	29	42	3	MM14802
Pathway	WP_PDGFRBETA_PATHWAY	JAK1 JAK2 STAT5B	8.51e-05	29	42	3	M39616
Pathway	KEGG_MEDICUS_REFERENCE_PRL_JAK_STAT_SIGNALING_PATHWAY	JAK2 STAT5B	8.62e-05	5	42	2	M49006
Pathway	REACTOME_SIGNALING_BY_CSF3_G_CSF	JAK1 JAK2 STAT5B	9.44e-05	30	42	3	M41825
Pathway	PID_IL2_STAT5_PATHWAY	JAK1 LCK STAT5B	9.44e-05	30	42	3	M234
Pathway	REACTOME_HS_GAG_BIOSYNTHESIS	HS6ST2 HS6ST1 HS6ST3	1.04e-04	31	42	3	M685
Pathway	WP_IL2_SIGNALING_PATHWAY	JAK1 JAK2 LCK STAT5B	1.27e-04	87	42	4	MM15915
Pathway	BIOCARTA_IFNG_PATHWAY	JAK1 JAK2	1.29e-04	6	42	2	MM1590
Pathway	BIOCARTA_IFNG_PATHWAY	JAK1 JAK2	1.29e-04	6	42	2	M22085
Pathway	REACTOME_INTERLEUKIN_2_FAMILY_SIGNALING	JAK2 LCK STAT5B	1.51e-04	35	42	3	MM15144
Pathway	REACTOME_SIGNALING_BY_SCF_KIT	JAK2 LCK STAT5B	1.78e-04	37	42	3	MM14564
Pathway	KEGG_MEDICUS_PATHOGEN_HTLV_1_P12_TO_JAK_STAT_SIGNALING_PATHWAY	JAK1 STAT5B	1.80e-04	7	42	2	M47581
Pathway	KEGG_MEDICUS_REFERENCE_GH_JAK_STAT_SIGNALING_PATHWAY	JAK2 STAT5B	1.80e-04	7	42	2	M47646
Pathway	KEGG_MEDICUS_REFERENCE_EGF_JAK_STAT_SIGNALING_PATHWAY	JAK1 STAT5B	1.80e-04	7	42	2	M47430
Pathway	REACTOME_ERYTHROPOIETIN_ACTIVATES_STAT5	JAK2 STAT5B	1.80e-04	7	42	2	M27907
Pathway	WP_IL3_SIGNALING_PATHWAY	JAK1 JAK2 LCK STAT5B	2.17e-04	100	42	4	MM15879
Pathway	WP_IL5_SIGNALING	JAK1 JAK2 STAT5B	2.25e-04	40	42	3	M39392
Pathway	BIOCARTA_STAT3_PATHWAY	JAK1 JAK2	2.40e-04	8	42	2	MM1576
Pathway	BIOCARTA_STAT3_PATHWAY	JAK1 JAK2	2.40e-04	8	42	2	M22063
Pathway	REACTOME_IFNG_SIGNALING_ACTIVATES_MAPKS	JAK1 JAK2	2.40e-04	8	42	2	M48010
Pathway	WP_MECHANISMS_ASSOCIATED_WITH_PLURIPOTENCY	MPL JAK1 RIF1 RBL2 KDM5C ZMYM2	2.48e-04	301	42	6	MM15983
Pathway	WP_IL2_SIGNALING	JAK1 LCK STAT5B	2.60e-04	42	42	3	M39536
Pathway	REACTOME_SIGNALING_BY_SCF_KIT	JAK2 LCK STAT5B	2.79e-04	43	42	3	M508
Pathway	REACTOME_MAPK1_ERK2_ACTIVATION	JAK1 JAK2	3.08e-04	9	42	2	M26918
Pathway	REACTOME_INTERLEUKIN_9_SIGNALING	JAK1 STAT5B	3.08e-04	9	42	2	M27861
Pathway	KEGG_MEDICUS_REFERENCE_CYTOKINE_JAK_STAT_SIGNALING_PATHWAY	JAK1 JAK2 STAT5B	3.20e-04	45	42	3	M47408
Pathway	REACTOME_MAPK3_ERK1_ACTIVATION	JAK1 JAK2	3.84e-04	10	42	2	M26896
Pathway	REACTOME_INTERLEUKIN_21_SIGNALING	JAK1 STAT5B	3.84e-04	10	42	2	M27898
Pathway	REACTOME_INTERLEUKIN_2_SIGNALING	LCK STAT5B	3.84e-04	10	42	2	MM15618
Pathway	REACTOME_INTERLEUKIN_3_INTERLEUKIN_5_AND_GM_CSF_SIGNALING	JAK1 JAK2 STAT5B	3.87e-04	48	42	3	M914
Pathway	WP_IL3_SIGNALING	JAK1 JAK2 STAT5B	4.12e-04	49	42	3	M39722
Pathway	REACTOME_SIGNALING_BY_LEPTIN	JAK2 STAT5B	4.69e-04	11	42	2	M27195
Pathway	REACTOME_INTERLEUKIN_6_SIGNALING	JAK1 JAK2	4.69e-04	11	42	2	M1014
Pathway	REACTOME_INTERLEUKIN_27_SIGNALING	JAK1 JAK2	4.69e-04	11	42	2	M27897
Pathway	REACTOME_GLYCOSAMINOGLYCAN_METABOLISM	CHST15 HS6ST2 HS6ST1 HS6ST3	4.78e-04	123	42	4	MM14623
Pathway	PID_PTP1B_PATHWAY	JAK2 LCK STAT5B	4.91e-04	52	42	3	M50
Pathway	REACTOME_GLYCOSAMINOGLYCAN_METABOLISM	CHST15 HS6ST2 HS6ST1 HS6ST3	5.24e-04	126	42	4	M695
Pathway	WP_IL4_SIGNALING	JAK1 JAK2 STAT5B	5.49e-04	54	42	3	M39720
Pathway	REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM	HS6ST2 HS6ST1 HS6ST3	5.49e-04	54	42	3	MM14633
Pathway	REACTOME_INTERLEUKIN_35_SIGNALLING	JAK1 JAK2	5.61e-04	12	42	2	M27860
Pathway	PID_IL2_1PATHWAY	JAK1 LCK STAT5B	5.79e-04	55	42	3	M122
Pathway	REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM	HS6ST2 HS6ST1 HS6ST3	6.43e-04	57	42	3	M692
Pathway	PID_SHP2_PATHWAY	JAK1 JAK2 LCK	6.43e-04	57	42	3	M100
Pathway	REACTOME_INTERLEUKIN_15_SIGNALING	JAK1 STAT5B	7.71e-04	14	42	2	M27858
Pathway	PID_IL5_PATHWAY	JAK2 STAT5B	7.71e-04	14	42	2	M135
Pathway	REACTOME_REGULATION_OF_IFNG_SIGNALING	JAK1 JAK2	7.71e-04	14	42	2	M942
Pathway	REACTOME_SIGNALING_BY_FGFR_IN_DISEASE	GTF2F2 ZMYM2 STAT5B	8.62e-04	63	42	3	M635
Pathway	REACTOME_PROLACTIN_RECEPTOR_SIGNALING	JAK2 STAT5B	8.88e-04	15	42	2	M552
Pathway	BIOCARTA_IL3_PATHWAY	JAK2 STAT5B	8.88e-04	15	42	2	MM1412
Pathway	BIOCARTA_IL3_PATHWAY	JAK2 STAT5B	8.88e-04	15	42	2	M17681
Pathway	PID_IL4_2PATHWAY	JAK1 JAK2 STAT5B	9.03e-04	64	42	3	M28
Pathway	WP_ONCOSTATIN_M_SIGNALING	JAK1 JAK2 STAT5B	9.45e-04	65	42	3	M39562
Pathway	WP_THYROID_STIMULATING_HORMONE_TSH_SIGNALING	JAK1 JAK2 RBL2	9.88e-04	66	42	3	M39684
Pathway	REACTOME_GROWTH_HORMONE_RECEPTOR_SIGNALING	JAK2 STAT5B	1.01e-03	16	42	2	MM15710
Pathway	WP_IL5_SIGNALING_PATHWAY	JAK1 JAK2 STAT5B	1.08e-03	68	42	3	MM15930
Pathway	WP_TH17_CELL_DIFFERENTIATION_PATHWAY	JAK1 JAK2 LCK	1.12e-03	69	42	3	M45541
Pathway	KEGG_JAK_STAT_SIGNALING_PATHWAY	MPL JAK1 JAK2 STAT5B	1.14e-03	155	42	4	M17411
Pathway	WP_NCRNAS_INVOLVED_IN_STAT3_SIGNALING_IN_HEPATOCELLULAR_CARCINOMA	JAK1 JAK2	1.15e-03	17	42	2	M39512
Pathway	REACTOME_IL_6_TYPE_CYTOKINE_RECEPTOR_LIGAND_INTERACTIONS	JAK1 JAK2	1.15e-03	17	42	2	M27612
Pathway	WP_IL9_SIGNALING	JAK1 STAT5B	1.15e-03	17	42	2	M39644
Pathway	REACTOME_METABOLISM_OF_CARBOHYDRATES	CHST15 HS6ST2 HS6ST1 NUP133 HS6ST3	1.20e-03	271	42	5	MM15406
Pathway	REACTOME_SIGNALING_BY_CYTOSOLIC_FGFR1_FUSION_MUTANTS	ZMYM2 STAT5B	1.29e-03	18	42	2	M673
Pathway	REACTOME_SIGNALING_BY_FLT3_FUSION_PROTEINS	ZMYM2 STAT5B	1.43e-03	19	42	2	M41732
Pathway	BIOCARTA_EPO_PATHWAY	JAK2 STAT5B	1.43e-03	19	42	2	M12836
Pathway	WP_LEPTIN_SIGNALING	JAK1 JAK2 STAT5B	1.49e-03	76	42	3	M39491
Pathway	WP_PROLACTIN_SIGNALING	JAK1 JAK2 STAT5B	1.49e-03	76	42	3	M39601
Pathway	REACTOME_METABOLISM_OF_CARBOHYDRATES	CHST15 HS6ST2 HS6ST1 NUP133 HS6ST3	1.57e-03	288	42	5	M16864
Pathway	REACTOME_INTERLEUKIN_20_FAMILY_SIGNALING	JAK2 STAT5B	1.59e-03	20	42	2	MM15496
Pathway	BIOCARTA_EPO_PATHWAY	JAK2 STAT5B	1.59e-03	20	42	2	MM1389
Pathway	WP_REGULATORY_CIRCUITS_OF_STAT3_SIGNALING	MPL JAK1 JAK2	1.60e-03	78	42	3	M39824
Pathway	BIOCARTA_IL6_PATHWAY	JAK1 JAK2	1.76e-03	21	42	2	M5489
Pathway	REACTOME_MITOCHONDRIAL_TRNA_AMINOACYLATION	KARS1 EARS2	1.76e-03	21	42	2	M15096
Pathway	KEGG_MEDICUS_REFERENCE_TYPE_II_INTERFERON_TO_JAK_STAT_SIGNALING_PATHWAY	JAK1 JAK2	1.76e-03	21	42	2	M47909
Pathway	BIOCARTA_IL6_PATHWAY	JAK1 JAK2	1.93e-03	22	42	2	MM1415
Pathway	WP_IMMUNE_RESPONSE_TO_TUBERCULOSIS	JAK1 JAK2	2.11e-03	23	42	2	M39748
Pathway	WP_BLOOD_CLOTTING_CASCADE	LPA F13B	2.11e-03	23	42	2	MM15936
Pathway	REACTOME_RAF_INDEPENDENT_MAPK1_3_ACTIVATION	JAK1 JAK2	2.11e-03	23	42	2	M26917
Pathway	BIOCARTA_GLEEVEC_PATHWAY	JAK2 STAT5B	2.11e-03	23	42	2	MM1424
Pathway	BIOCARTA_GLEEVEC_PATHWAY	JAK2 STAT5B	2.11e-03	23	42	2	M7897
Pathway	KEGG_MEDICUS_REFERENCE_IL2_FAMILY_TO_JAK_STAT_SIGNALING_PATHWAY	JAK1 STAT5B	2.11e-03	23	42	2	M47904
Pathway	REACTOME_INTERLEUKIN_6_FAMILY_SIGNALING	JAK1 JAK2	2.29e-03	24	42	2	M27604
Pathway	REACTOME_GROWTH_HORMONE_RECEPTOR_SIGNALING	JAK2 STAT5B	2.29e-03	24	42	2	M519
Pathway	REACTOME_DISEASES_OF_SIGNAL_TRANSDUCTION_BY_GROWTH_FACTOR_RECEPTORS_AND_SECOND_MESSENGERS	JAK2 FZD8 GTF2F2 ZMYM2 LCK STAT5B	2.36e-03	464	42	6	M27547
Pubmed	Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.	JAK1 JAK2 LCK	4.40e-09	3	58	3	9548458
Pubmed	Differential expression of heparan sulfate 6-O-sulfotransferase isoforms in the mouse embryo suggests distinctive roles during organogenesis.	HS6ST2 HS6ST1 HS6ST3	4.40e-09	3	58	3	15499561
Pubmed	Substrate specificities of mouse heparan sulphate glucosaminyl 6-O-sulphotransferases.	HS6ST2 HS6ST1 HS6ST3	4.40e-09	3	58	3	12611590
Pubmed	The occurrence of three isoforms of heparan sulfate 6-O-sulfotransferase having different specificities for hexuronic acid adjacent to the targeted N-sulfoglucosamine.	HS6ST2 HS6ST1 HS6ST3	4.40e-09	3	58	3	10644753
Pubmed	Heparan sulfate 6-O-sulfotransferase isoform-dependent regulatory effects of heparin on the activities of various proteases in mast cells and the biosynthesis of 6-O-sulfated heparin.	HS6ST2 HS6ST1 HS6ST3	4.40e-09	3	58	3	23223449
Pubmed	Overexpression of heparan sulfate 6-O-sulfotransferases in human embryonic kidney 293 cells results in increased N-acetylglucosaminyl 6-O-sulfation.	HS6ST2 HS6ST1 HS6ST3	4.40e-09	3	58	3	16326709
Pubmed	Stem domains of heparan sulfate 6-O-sulfotransferase are required for Golgi localization, oligomer formation and enzyme activity.	HS6ST2 HS6ST1 HS6ST3	1.76e-08	4	58	3	15226404
Pubmed	Loss of JAK1 Drives Innate Immune Deficiency.	JAK1 JAK2 STAT5B	1.76e-08	4	58	3	30671064
Pubmed	Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.	JAK1 JAK2 STAT5B	1.76e-08	4	58	3	23406773
Pubmed	Box 2 region of the oncostatin M receptor determines specificity for recruitment of Janus kinases and STAT5 activation.	JAK1 JAK2 STAT5B	1.76e-08	4	58	3	18430728
Pubmed	Analysis of axon guidance defects at the optic chiasm in heparan sulphate sulphotransferase compound mutant mice.	HS6ST2 HS6ST1 HS6ST3	1.76e-08	4	58	3	21951307
Pubmed	Dual mechanism of signal transducer and activator of transcription 5 activation by the insulin receptor.	JAK1 JAK2 STAT5B	4.39e-08	5	58	3	12456798
Pubmed	An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT.	JAK1 JAK2 STAT5B	4.39e-08	5	58	3	9047382
Pubmed	Sulfatase 1 is an inhibitor of ductal morphogenesis with sexually dimorphic expression in the urogenital sinus.	HS6ST2 HS6ST1 HS6ST3	1.53e-07	7	58	3	20410206
Pubmed	A Stat3-interacting protein (StIP1) regulates cytokine signal transduction.	JAK1 JAK2 STAT5B	1.53e-07	7	58	3	10954736
Pubmed	Mice deficient in heparan sulfate 6-O-sulfotransferase-1 exhibit defective heparan sulfate biosynthesis, abnormal placentation, and late embryonic lethality.	HS6ST2 HS6ST1 HS6ST3	2.45e-07	8	58	3	17405882
Pubmed	The Jak-STAT pathway.	JAK1 JAK2 STAT5B	3.67e-07	9	58	3	10781830
Pubmed	Lacrimal gland development and Fgf10-Fgfr2b signaling are controlled by 2-O- and 6-O-sulfated heparan sulfate.	HS6ST2 HS6ST1 HS6ST3	3.67e-07	9	58	3	21357686
Pubmed	Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains.	JAK1 JAK2 STAT5B	3.67e-07	9	58	3	9484840
Pubmed	Activation of protein kinase C delta by IFN-gamma.	JAK1 JAK2 LCK	3.67e-07	9	58	3	12817007
Pubmed	A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma.	JAK1 JAK2 LCK	5.24e-07	10	58	3	7690989
Pubmed	Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling.	JAK1 JAK2 STAT5B	5.24e-07	10	58	3	20974963
Pubmed	Cytokines, Jaks, Stats, health and disease.	JAK1 JAK2 STAT5B	5.24e-07	10	58	3	10200816
Pubmed	Developmental and regional expression of heparan sulfate sulfotransferase genes in the mouse brain.	HS6ST2 HS6ST1 HS6ST3	7.19e-07	11	58	3	15944372
Pubmed	Protein kinase Cdelta regulates apoptosis via activation of STAT1.	JAK1 JAK2 LCK	7.19e-07	11	58	3	15322115
Pubmed	Involvement of heparan sulfate 6-O-sulfation in the regulation of energy metabolism and the alteration of thyroid hormone levels in male mice.	HS6ST2 HS6ST1 HS6ST3	7.19e-07	11	58	3	23690091
Pubmed	Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.	JAK1 JAK2 LCK	7.19e-07	11	58	3	7543024
Pubmed	Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.	JAK1 JAK2 LCK	9.58e-07	12	58	3	10918587
Pubmed	Variant heparan sulfates synthesized in developing mouse brain differentially regulate FGF signaling.	HS6ST2 HS6ST1 HS6ST3	9.58e-07	12	58	3	12460940
Pubmed	Ser727/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0/G1 arrest of U-937 cells.	JAK1 JAK2 LCK	9.58e-07	12	58	3	12637327
Pubmed	Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism.	JAK1 RIF1 GTF2F2 KARS1 EARS2 FAM120C ZMYM2	1.60e-06	341	58	7	32971831
Pubmed	Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727.	JAK1 JAK2 LCK	1.97e-06	15	58	3	11839738
Pubmed	Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes.	MPL JAK2	2.73e-06	2	58	2	17507998
Pubmed	A structure-function analysis of serine/threonine phosphorylation of the thrombopoietin receptor, c-Mpl.	MPL JAK2	2.73e-06	2	58	2	10918061
Pubmed	Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.	JAK1 JAK2	2.73e-06	2	58	2	28645562
Pubmed	Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2.	JAK1 JAK2	2.73e-06	2	58	2	35382859
Pubmed	Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.	MPL JAK2	2.73e-06	2	58	2	17920755
Pubmed	The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.	MPL JAK2	2.73e-06	2	58	2	17920754
Pubmed	Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.	MPL JAK1	2.73e-06	2	58	2	21051030
Pubmed	JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms.	MPL JAK2	2.73e-06	2	58	2	27865175
Pubmed	Mpl traffics to the cell surface through conventional and unconventional routes.	MPL JAK2	2.73e-06	2	58	2	24931576
Pubmed	The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.	MPL JAK2	2.73e-06	2	58	2	20304805
Pubmed	Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation-loop mutation.	JAK1 JAK2	2.73e-06	2	58	2	24169825
Pubmed	JAK2 and MPL mutations in myeloproliferative neoplasms.	MPL JAK2	2.73e-06	2	58	2	18566540
Pubmed	Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity.	MPL JAK2	2.73e-06	2	58	2	19261614
Pubmed	Novel signal transduction pathway for luteinizing hormone and its interaction with insulin: activation of Janus kinase/signal transducer and activator of transcription and phosphoinositol 3-kinase/Akt pathways.	JAK2 STAT5B	2.73e-06	2	58	2	12538627
Pubmed	[MPLW515L point mutation in patients with myeloproliferative disease].	MPL JAK2	2.73e-06	2	58	2	19099657
Pubmed	MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.	MPL JAK2	2.73e-06	2	58	2	21326037
Pubmed	Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis.	MPL JAK2	2.73e-06	2	58	2	20520633
Pubmed	Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.	MPL JAK2	2.73e-06	2	58	2	22378845
Pubmed	Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden.	MPL JAK2	2.73e-06	2	58	2	26419289
Pubmed	[Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].	MPL JAK2	2.73e-06	2	58	2	19175989
Pubmed	Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction.	MPL JAK2	2.73e-06	2	58	2	19521067
Pubmed	Stimulation of the amino acid transporter SLC6A19 by JAK2.	JAK2 SLC6A19	2.73e-06	2	58	2	21964291
Pubmed	Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.	MPL JAK2	2.73e-06	2	58	2	18519816
Pubmed	Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.	JAK1 JAK2	2.73e-06	2	58	2	21393331
Pubmed	Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.	JAK1 JAK2	2.73e-06	2	58	2	25977345
Pubmed	Ovarian cancer cell heparan sulfate 6-O-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (EGF)-like growth factor/EGF receptor signaling.	HS6ST2 HS6ST1	2.73e-06	2	58	2	24563483
Pubmed	Biosynthesis of heparan sulphate with diverse structures and functions: two alternatively spliced forms of human heparan sulphate 6-O-sulphotransferase-2 having different expression patterns and properties.	HS6ST2 HS6ST1	2.73e-06	2	58	2	12492399
Pubmed	Gene conversion and purifying selection of a placenta-specific ERV-V envelope gene during simian evolution.	ERVV-2 ERVV-1	2.73e-06	2	58	2	18826608
Pubmed	The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo.	JAK1 JAK2	2.73e-06	2	58	2	24158701
Pubmed	Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms.	MPL JAK2	2.73e-06	2	58	2	23986553
Pubmed	MPL W515L mutation in Chinese patients with myeloproliferative diseases.	MPL JAK2	2.73e-06	2	58	2	18464114
Pubmed	WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.	MPL JAK2	2.73e-06	2	58	2	20485371
Pubmed	Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.	JAK1 JAK2	2.73e-06	2	58	2	22684105
Pubmed	The membrane-proximal region of the thrombopoietin receptor confers its high surface expression by JAK2-dependent and -independent mechanisms.	MPL JAK2	2.73e-06	2	58	2	17052978
Pubmed	JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.	MPL JAK2	2.73e-06	2	58	2	22565617
Pubmed	JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.	MPL JAK2	2.73e-06	2	58	2	19643476
Pubmed	The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts.	JAK2 STAT5B	2.73e-06	2	58	2	26084564
Pubmed	Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1.	MPL JAK2	2.73e-06	2	58	2	10979953
Pubmed	JAK2 tyrosine kinase phosphorylates and is negatively regulated by centrosomal protein Ninein.	JAK2 NIN	2.73e-06	2	58	2	25332239
Pubmed	SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation.	JAK1 JAK2	2.73e-06	2	58	2	33827897
Pubmed	Clinical acceleration of JAK2 p.V617F driven myeloproliferative disease due to a new uncommon homozygous MPL p.Y591D mutation.	MPL JAK2	2.73e-06	2	58	2	32499240
Pubmed	MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.	MPL JAK2	2.73e-06	2	58	2	16868251
Pubmed	Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.	MPL JAK2	2.73e-06	2	58	2	19372714
Pubmed	JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.	MPL JAK2	2.73e-06	2	58	2	18754026
Pubmed	Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.	MPL JAK2	2.73e-06	2	58	2	17540852
Pubmed	Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase.	JAK1 JAK2	2.73e-06	2	58	2	1848670
Pubmed	Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.	JAK1 JAK2	2.73e-06	2	58	2	29508247
Pubmed	The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.	MPL JAK2	2.73e-06	2	58	2	18250227
Pubmed	The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.	MPL JAK2	2.73e-06	2	58	2	20331763
Pubmed	Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation.	MPL JAK2	2.73e-06	2	58	2	19196872
Pubmed	JAK2 V617F and MPL W515L/K mutations in Korean patients with essential thrombocythemia.	MPL JAK2	2.73e-06	2	58	2	20890078
Pubmed	Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease.	JAK1 JAK2	2.73e-06	2	58	2	33811972
Pubmed	Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis.	MPL JAK2	2.73e-06	2	58	2	20151976
Pubmed	MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 x 10(9)/l.	MPL JAK2	2.73e-06	2	58	2	18040685
Pubmed	Studies with chimeric Mpl/JAK2 receptors indicate that both JAK2 and the membrane-proximal domain of Mpl are required for cellular proliferation.	MPL JAK2	2.73e-06	2	58	2	11980901
Pubmed	The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms.	MPL JAK2	2.73e-06	2	58	2	28744010
Pubmed	Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.	JAK1 JAK2	2.73e-06	2	58	2	29263442
Pubmed	Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations.	MPL JAK2	2.73e-06	2	58	2	20113830
Pubmed	Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.	JAK1 JAK2	2.73e-06	2	58	2	27222478
Pubmed	Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.	JAK1 JAK2	2.73e-06	2	58	2	27903500
Pubmed	Two members of the JAK family of protein tyrosine kinases map to chromosomes 1p31.3 and 9p24.	JAK1 JAK2	2.73e-06	2	58	2	1581631
Pubmed	Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.	MPL JAK2	2.73e-06	2	58	2	31135094
Pubmed	A constitutively active Lck kinase promotes cell proliferation and resistance to apoptosis through signal transducer and activator of transcription 5b activation.	LCK STAT5B	2.73e-06	2	58	2	16446405
Pubmed	Differential evolutionary fate of an ancestral primate endogenous retrovirus envelope gene, the EnvV syncytin, captured for a function in placentation.	ERVV-2 ERVV-1	2.73e-06	2	58	2	23555306
Pubmed	Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.	JAK1 JAK2	2.73e-06	2	58	2	19887489
Pubmed	CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.	JAK1 JAK2	8.19e-06	3	58	2	26175413
Pubmed	MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.	MPL JAK2	8.19e-06	3	58	2	33361847
Pubmed	[Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease].	MPL JAK2	8.19e-06	3	58	2	28766534
Interaction	IL2RB interactions	JAK1 JAK2 LCK STAT5B	2.74e-06	36	55	4	int:IL2RB
Interaction	CCR5 interactions	JAK1 JAK2 LCK STAT5B	9.60e-06	49	55	4	int:CCR5
Interaction	CRLF2 interactions	SLC25A46 JAK1 JAK2 HS6ST1	2.31e-05	61	55	4	int:CRLF2
Interaction	CSF3R interactions	JAK1 JAK2 LCK	7.41e-05	30	55	3	int:CSF3R
Interaction	PARP9 interactions	JAK1 JAK2 HELZ2	9.02e-05	32	55	3	int:PARP9
Interaction	CSF2RB interactions	JAK1 JAK2 LCK	9.02e-05	32	55	3	int:CSF2RB
Interaction	TUB interactions	JAK2 KDM5C LCK	9.90e-05	33	55	3	int:TUB
GeneFamily	Sulfotransferases, membrane bound	CHST15 HS6ST2 HS6ST1 HS6ST3	1.42e-06	37	41	4	763
GeneFamily	Polypeptide N-acetylgalactosaminyltransferases	GALNT15 GALNT9	9.29e-04	20	41	2	433
GeneFamily	SH2 domain containing	JAK2 LCK STAT5B	1.55e-03	101	41	3	741
Coexpression	GSE3982_EOSINOPHIL_VS_MAC_UP	JAK1 DSC3 INPP5A NUP133 RANBP6	6.38e-05	197	56	5	M5401
Coexpression	GSE17721_CPG_VS_GARDIQUIMOD_8H_BMDC_UP	RIF1 GTF2F2 KDM5C NUP133 NECTIN3	6.69e-05	199	56	5	M3892
Coexpression	GSE22935_UNSTIM_VS_24H_MBOVIS_BCG_STIM_MACROPHAGE_DN	GTF2F2 KARS1 CHST15 RNF19B NSMAF	6.85e-05	200	56	5	M7750
Coexpression	GSE15750_WT_VS_TRAF6KO_DAY6_EFF_CD8_TCELL_DN	EARS2 FAM120C SUSD2 GALNT9 SLC6A19	6.85e-05	200	56	5	M3571
Coexpression	GSE15750_DAY6_VS_DAY10_EFF_CD8_TCELL_DN	CREBRF MDN1 SUSD2 HS6ST1 NEURL4	6.85e-05	200	56	5	M3579
Coexpression	GSE40274_FOXP3_VS_FOXP3_AND_GATA1_TRANSDUCED_ACTIVATED_CD4_TCELL_UP	MPL PRUNE2 C16orf96 F13B NSMAF	6.85e-05	200	56	5	M9186
Coexpression	TRAYNOR_RETT_SYNDROM_UP	GALNT15 PRUNE2 LTBP1	8.63e-05	40	56	3	M2712
Coexpression	CHENG_IMPRINTED_BY_ESTRADIOL	FZD8 KARS1 C22orf23 HS6ST2	9.12e-05	110	56	4	M19202
ToppCell	Adult-Epithelial-basal_cell-D231\|Adult / Lineage, Cell type, age group and donor	DSC3 C22orf23 HS6ST2 LPA KIAA1217	3.17e-06	174	58	5	a4f98afe7d1cc2617f6f7bc8092c41df57474b30
ToppCell	Adult-Epithelial-basal_cell\|Adult / Lineage, Cell type, age group and donor	DSC3 C22orf23 HS6ST2 LPA KIAA1217	4.06e-06	183	58	5	00a6b19ca49e3b8e0d1cd387a3515b0ff4b81c81
Disease	Polycythemia Vera	MPL JAK1 JAK2	3.41e-07	8	55	3	C0032463
Disease	Myeloproliferative disease	MPL JAK2 ZMYM2	1.33e-06	12	55	3	C0027022
Disease	Deep Vein Thrombosis	JAK2 LPA F13B	7.96e-06	21	55	3	C0149871
Disease	Venous Thrombosis	JAK2 LPA F13B	7.96e-06	21	55	3	C0042487
Disease	Familial thrombocytosis	MPL JAK2	1.02e-05	3	55	2	C4303761
Disease	Thrombocytosis	MPL JAK2	1.02e-05	3	55	2	C0836924
Disease	MYELOFIBROSIS	MPL JAK2	2.04e-05	4	55	2	254450
Disease	Myelofibrosis	MPL JAK2	2.04e-05	4	55	2	C0026987
Disease	Primary myelofibrosis	MPL JAK2	2.04e-05	4	55	2	cv:C0001815
Disease	Essential thrombocythemia	MPL JAK2	3.40e-05	5	55	2	cv:C0040028
Disease	thrombocytosis (is_implicated_in)	MPL JAK2	3.40e-05	5	55	2	DOID:2228 (is_implicated_in)
Disease	Primary Myelofibrosis	MPL JAK2	5.09e-05	6	55	2	C0001815
Disease	myelofibrosis (implicated_via_orthology)	MPL JAK2	5.09e-05	6	55	2	DOID:4971 (implicated_via_orthology)
Disease	essential thrombocythemia (is_implicated_in)	MPL JAK2	5.09e-05	6	55	2	DOID:2224 (is_implicated_in)
Disease	disease of cellular proliferation (implicated_via_orthology)	JAK1 JAK2	7.12e-05	7	55	2	DOID:14566 (implicated_via_orthology)
Disease	myelofibrosis (is_implicated_in)	MPL JAK2	9.48e-05	8	55	2	DOID:4971 (is_implicated_in)
Disease	Thromboembolism	JAK2 LPA	2.22e-04	12	55	2	C0040038
Disease	Hematologic Neoplasms	MPL JAK2	2.22e-04	12	55	2	C0376545
Disease	Thrombocythemia, Essential	MPL JAK2	2.22e-04	12	55	2	C0040028
Disease	hematologic cancer (implicated_via_orthology)	JAK1 JAK2	2.63e-04	13	55	2	DOID:2531 (implicated_via_orthology)
Disease	Antihistamine use measurement	SLC25A46 RANBP6	4.56e-04	17	55	2	EFO_0009943
Disease	colon adenocarcinoma (is_implicated_in)	JAK2 STAT5B	1.08e-03	26	55	2	DOID:234 (is_implicated_in)
Disease	cytotoxicity measurement, response to clozapine	CHST15 NSMAF	1.34e-03	29	55	2	EFO_0006952, GO_0097338
Disease	allergic disease	SLC25A46 JAK2 RANBP6 STAT5B	1.37e-03	258	55	4	MONDO_0005271
Disease	asthma, seasonal allergic rhinitis	SLC25A46 RANBP6	1.63e-03	32	55	2	EFO_0003956, MONDO_0004979

Protein segments in the cluster

Peptide	Gene	Start	Entry
VNPMESYQNRQSCVT	CLSTN3	906	Q9BQT9
DREMNYQQNPRDNFL	CREBRF	46	Q8IUR6
NERPSAYMREHNQLN	GPNMB	31	Q14956
MNDYRDKSPQNRCAA	ERVV-2	171	B6SEH9
ALMAACRARYDDPQN	ANKRD34A	41	Q69YU3
ADLMTRCMNYDPNQR	JAK1	821	P23458
ANLINNCMDYEPDFR	JAK2	781	O60674
NIMRCYRTQPQARSQ	RBL2	911	Q08999
CEQTDNQSRLQRYMT	NUP133	876	Q8WUM0
PANMCQANGAYSREQ	C22orf23	96	Q9BZE7
PQCRVVADRMDNNAN	DIO2	206	Q92813
PESRRQEYMQNCEQL	MDN1	3151	Q9NU22
CRQMSYAQDLPQVSV	GALNT9	141	Q9HCQ5
LSNERCQQQMPEYNI	TMPRSS15	936	P98073
MVLAPCSDSRQQQYL	GALNT15	531	Q8N3T1
MNDYRDKSPQNRCAA	ERVV-1	171	B6SEH8
ANRENGSQAMPYNCR	NHSL1	511	Q5SYE7
LEPCTVNVDYMNRNN	F13B	451	P05160
RNKNEVFYQCPDQMA	FBXO3	216	Q9UK99
EDARQGEQYMNTRCP	INPP5A	331	Q14642
ENQEYSPMTGQCRSR	LTBP1	1316	Q14766
QNLERGYRMVRPDNC	LCK	451	P06239
QEFMDCPYNLANNRQ	HS6ST1	236	O60243
CPYNLANNRQVRMLA	HS6ST1	241	O60243
REFMDCTYNLANNRQ	HS6ST3	296	Q8IZP7
CTYNLANNRQVRMLA	HS6ST3	301	Q8IZP7
AAYQPDQMRSAEQTR	PASD1	746	Q8IV76
EMYQQNKDARCCNPS	MCHR2	226	Q969V1
QGNPDTLCMDYNRTD	FZD8	141	Q9H461
CNQNEDRMPSQDYVL	DSC3	836	Q14574
PASANSCEYLQRQQM	C16orf96	941	A6NNT2
ALPNMNRENREQYQV	CDH10	221	Q9Y6N8
RQMPCEAVSSYINRD	POLQ	1216	O75417
DSNECNNGNRYLPMN	FAM120C	1061	Q9NX05
NAGLIMNYCRNPDAV	LPA	411	P08519
APEYMLCLQNGRFDN	NSMAF	406	Q92636
CPYNLANNRQVRMLS	HS6ST2	381	Q96MM7
GVRVTCNQPLMYQAQ	HELZ2	161	Q9BYK8
CNQPLMYQAQERKTQ	HELZ2	166	Q9BYK8
GMNNQYTRREVFCRN	FAM240A	6	A0A1B0GVK7
SCEVRRDGQLQRMNY	NEURL4	1011	Q96JN8
VQRAECRPAASENYM	GTF2F2	111	P13984
CPRYMQRRPSNDCRN	SUSD2	426	Q9UGT4
VDMQQRCNASDPAAY	SLC6A19	361	Q695T7
SYNPQDRECNNMEIQ	RNF19B	576	Q6ZMZ0
EQQPRRQIAVYSENM	PRUNE2	286	Q8WUY3
CNAYTELNDPMRQRQ	KARS1	496	Q15046
MRNEYERQCRVLQDQ	NIN	536	Q8N4C6
RCDIPAMYNNLDVSQ	RIF1	1076	Q5UIP0
PCLPYSADRRQMQEQ	KIAA1217	11	Q5T5P2
ATQLQNTYDRCPMEL	STAT5B	91	P51692
NMRDNNPEVRQAAAY	RANBP6	921	O60518
PQSIQQAMRYLRSQC	STARD8	586	Q92502
RNHQTPRYDNRCRNM	EARS2	156	Q5JPH6
PRYDNRCRNMSQEQV	EARS2	161	Q5JPH6
RACVYNNTLNNAMPV	CHST15	436	Q7LFX5
PINTQYEGMRDCINT	SLC25A46	361	Q96AG3
PLCSSQAQMDYRRLQ	MPL	581	P40238
QAQMDYRRLQPSCLG	MPL	586	P40238
LLRFYCQQNEPNMTT	ZMYM2	796	Q9UBW7
YQTQVQDNRCMDRRF	WSCD2	321	Q2TBF2
MYQSGANLVQCNTRP	KDM5C	166	P41229
NNVENLNRFERPMDY	NECTIN3	496	Q9NQS3